Climb Bio gets Deutsche Bank Buy rating and $28 target price
CLYM•Deutsche Bank initiated coverage of Climb Bio with a Buy rating and a $28 target price.
Related News
Actinium's ATNM-400 achieves 93% tumor growth inhibition in preclinical ovarian cancer model
ATNM•
Ally Financial Q3 adjusted revenue beats estimates
ALLY•
United Community Banks forecasts Q4 EPS of $0.80-$0.83
UCB•
Kroger up after it unveils long-term targets ahead of investor day
KR•
Nasdaq futures fall as oil prices jump, key earnings loom
SPY•